Why Grail Could Be the Sleeper Stock Everyone's About to Notice

Grail is a leader in the potentially enormous multi-cancer early detection (MCED) test market. The company could have a major catalyst on the way with the potential FDA approval of its Galleri test.

The Motley Fool • 7 hours ago

GRAL INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Grail, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm

ATLANTA, June 08, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Grail, Inc. (“Grail”) (NASDAQ: GRAL). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts regarding the probability of achieving the primary endpoint of a statistically significant reduction in Stage III-IV cancers in Grail's NHS-Galleri trial.

GlobeNewsWire • 2 hours ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Grail, Inc. (GRAL)

NEW YORK, June 08, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Grail, Inc. (“Grail” or the “Company”) (NASDAQ: GRAL) securities between May 13, 2025 and February 19, 2026, inclusive (the “Class Period”).

GlobeNewsWire • an hour ago

SHAREHOLDER CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Deadline on August 4, 2026

NEW YORK--(BUSINESS WIRE)---- $GRAL #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Grail, Inc. (“Grail” or the “Company”) (NASDAQ: GRAL) and reminds investors of the August 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recover.

Business Wire • Jun 7, 2026

Here's Why Grail Stock Soared Higher in May (And Where the Company is Heading Now)

NHS Galleri trial missed primary endpoint but showed positive trends in deadly cancers. FDA approval and further trial follow-up are key upcoming catalysts.

The Motley Fool • Jun 5, 2026

GRAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Deadline on August 4, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suffered Losses In Grail To Contact Him Directly To Discuss Their Options

GlobeNewsWire • Jun 5, 2026

GRAL INVESTOR ALERT: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead the Grail Class Action Lawsuit – RGRD Law

SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the Grail class action lawsuit seeks to represent purchasers or acquirers of GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025 and February 19, 2026, inclusive (the “Class Period”). Captioned Robbins v.

GlobeNewsWire • Jun 5, 2026

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of GRAIL, Inc. Common Stock and Sets a Lead Plaintiff Deadline of August 4, 2026

NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired common stock of GRAIL, Inc. (“GRAIL” or the “Company”) (NASDAQ: GRAL) between May 13, 2025, and February 19, 2026, inclusive. You are hereby notified that the class action lawsuit William Robbins v.

GlobeNewsWire • Jun 5, 2026

Investor Notice: Robbins LLP Informs Investors of the Grail, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)---- $GRAL #Grail--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Grail, Inc. (NASDAQ: GRAL) securities between May 13, 2025, and February 19, 2026. Grail, Inc. describes itself as a commercial stage healthcare company with a focus on early cancer detection through screening methodology.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: R.

Business Wire • Jun 5, 2026

Is Grail Stock a Bad-News Buy After Its Recent Pullback?

Grail's stock stumbled after a major trial failed to meet its primary endpoint. But it's still selling thousands of tests without the FDA's approval.

The Motley Fool • Jun 4, 2026